MedTrace Logo

Pentoxifylline Administration in Hemodialysis Patients

NCT03800433 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2019-09-25

No results posted yet for this study

Summary

The aim of the study is to assess the impact of pentoxifylline administration on the modulation of hyporesponsiveness to erythropoietin stimulating agents in hemodialysis patients

Conditions

  • Anemia Renal

Interventions

DRUG

Trental 400 MG Extended Release Oral Tablet

oral tablets

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Lamia El Wakeel, Ass.Prof · Ass.prof clinical pharmacy

  • Radwa El Borolossy, Phd · Lecturer of clinical pharmacy

  • Magdy ElSharkawy, Prof.Dr. · Prof. of nephrology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2020-04-30
Completion
2020-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03800433 on ClinicalTrials.gov